Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Polepally, Akshanth
Badillo, Jesus D.
de Almeida, Carla Biesdorf
Voorhees, Peter M.
D'Souza, Anita
Kumar, Shaji
Bueno, Orlando Felix
Rosenberg, Tanya
Pothacamury, Rajvineeth Kumar
Talati, Chetasi
Menon, Rajeev
Mensing, Sven
Engelhardt, Benjamin
机构：
[1] AbbVie Inc, Ludwigshafen, Germany
[2] Wake Forest Univ, Levine Canc Inst, Plasma Cell Disorders Sect,Atrium Hlth, Dept Hematol Oncol & Blood Disorders,Sch Med, Charlotte, NC USA
[3] Froedtert & Med Coll Wisconsin Canc Ctr, Div Hematol Oncol, Dept Med, Milwaukee, WI USA
[4] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7541
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma
    Ferron-Brady, Geraldine
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Visser, Sandra
    Jewell, Roxanne C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1282 - 1292
  • [2] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    Ahsan, Aarif
    Mantis, Christine
    Luo, Xizhi
    Zhang, Catherine C.
    Valdes, Cesar Rodriguez
    Voorhees, Peter M.
    D'Souza, Anita
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Mckay, John T.
    Weisel, Katja C.
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Kumar, Shaji
    Bueno, Orlando Felix
    Pothacamury, Rajvineeth Kumar
    Talati, Chetasi
    Ross, Jeremy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    Valdes, Cesar Rodriguez
    Voorhees, Peter M.
    D'Souza, Anita
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Mckay, John T.
    Weisel, Katja C.
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Bueno, Orlando Felix
    Rosenberg, Tanya
    Pothacamury, Rajvineeth Kumar
    Polepally, Akshanth
    Ahsan, Aarif
    Li , Xin
    Jin, Ziyi
    Talati, Chetasi
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma
    Rodriguez, Cesar
    Weisel, Katja
    Baz, Rachid C.
    Polepally, Akshanth R.
    Ross, Jeremy A.
    Jin, Ziyi
    D'Amico, Kristin
    Bueno, Orlando F.
    Fleming, Leanne Lash
    Voorhees, Peter M.
    BLOOD, 2022, 140 : 7326 - 7327
  • [5] CERVINO: A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared With Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
    Costa, Luciano
    Mateos Manteca, Maria-Victoria
    Voorhees, Peter M.
    Iida, Shinsuke
    Cole, Craig
    Quach, Hang
    Pothacamury, Rajvineeth
    Bueno, Orlando
    Lee, Shane
    Rosenberg, Tanya
    Talati, Chetasi
    Kumar, Shaji
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S47 - S48
  • [6] Phase Ib Study Investigating the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Administration of ABBV-383 in Patients With Relapsed/Refractory Multiple Myeloma
    Gatt, Moshe
    Magen, Hila
    McKay, John
    Karlin, Lionel
    Touzeau, Cyrille
    Vincent, Laure
    Kapoor, Prashant
    Leleu, Xavier
    Uchida, Toshiki
    Weisel, Katja
    Bueno, Orlando
    Rosenberg, Tanya
    Ahsan, Aarif
    Jin, Ziyi
    Polepally, Akshanth
    Talati, Chetasi
    Pothacamury, Rajvineeth
    Chhabra, Saurabh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S54 - S55
  • [7] Exposure-Response Analyses of Various Efficacy and Safety Endpoints in Support of Registrational Dose Selection of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma
    Milberg, Oleg
    Chiu, Joannellyn
    Hazra, Anasuya
    Upadhyay, Sameer
    Kroog, Glenn S.
    Lorenc, Karen Rodriguez
    Davis, John D.
    Dicioccio, A. Thomas
    Harnisch, Lutz O.
    Chittenden, Jason
    BLOOD, 2024, 144 : 7056 - 7057
  • [8] Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial
    D'Souza, Anita
    Rodriguez-Valdes, Cesar
    Kumar, Shaji
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Weisel, Katja
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Bueno, Orlando
    Rosenberg, Tanya
    Pothacamury, Rajvineeth
    Polepally, Akshanth
    Ahsan, Aarif
    Lee, Shane
    Jin, Ziyi
    Spence, Shelli
    Talati, Chetasi
    McKay, John
    Voorhees, Peter M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S48 - S48
  • [9] ELRANATAMAB INTEGRATED EXPOSURE-RESPONSE (ER) EFFICACY AND SAFETY ANALYSES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) USING A CLINICAL UTILITY INDEX (CUI)
    Abdelgawad, I.
    Lon, H.
    Soltantabar, P.
    Hibma, J.
    Czibere, A.
    Wang, D.
    Elmeliegy, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S64 - S64
  • [10] Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
    Connarn, Jamie N.
    Witjes, Han
    van Zutphen-van Geffen, Marielle
    de Greef, Rik
    Campbell, Timothy B.
    Hege, Kristen
    Zhou, Simon
    Lamba, Manisha
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (11): : 1687 - 1697
12345